Lydie Hazan

749 total citations
12 papers, 244 citations indexed

About

Lydie Hazan is a scholar working on Infectious Diseases, Nutrition and Dietetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lydie Hazan has authored 12 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 4 papers in Nutrition and Dietetics and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lydie Hazan's work include Sodium Intake and Health (3 papers), HIV/AIDS drug development and treatment (3 papers) and Blood Pressure and Hypertension Studies (3 papers). Lydie Hazan is often cited by papers focused on Sodium Intake and Health (3 papers), HIV/AIDS drug development and treatment (3 papers) and Blood Pressure and Hypertension Studies (3 papers). Lydie Hazan collaborates with scholars based in United States, Australia and Japan. Lydie Hazan's co-authors include Reinilde Heyrman, Ben Tao, Koichi Miyazaki, As’ad E. Bhorat, Jennifer S. Li, Rakhi Kilaru, Ronald J. Portman, Katherine Berezny, Ronald J. Hogg and David Deitchman and has published in prestigious journals such as Blood, Hypertension and Journal of Hepatology.

In The Last Decade

Lydie Hazan

12 papers receiving 240 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lydie Hazan United States 8 95 56 45 44 40 12 244
Abiodun Adefurin United States 9 37 0.4× 17 0.3× 67 1.5× 13 0.3× 13 0.3× 10 293
Patrizia Morelli Italy 13 44 0.5× 89 1.6× 71 1.6× 20 0.5× 9 0.2× 29 504
Mahroo Rezaeinejad Iran 10 18 0.2× 33 0.6× 57 1.3× 22 0.5× 51 1.3× 16 351
Nicholas W. Carris United States 10 72 0.8× 124 2.2× 26 0.6× 11 0.3× 15 0.4× 37 287
Nancy Greenberg United States 7 368 3.9× 15 0.3× 43 1.0× 9 0.2× 31 0.8× 8 518
Parker Ra United States 10 161 1.7× 21 0.4× 115 2.6× 13 0.3× 8 0.2× 20 445
Valentino Conti Italy 10 40 0.4× 20 0.4× 27 0.6× 31 0.7× 5 0.1× 16 276
Michaël Thy France 10 20 0.2× 32 0.6× 114 2.5× 15 0.3× 5 0.1× 47 364
Junko Mochizuki Japan 10 27 0.3× 14 0.3× 41 0.9× 4 0.1× 18 0.5× 25 312
Philip Macarthy United States 13 30 0.3× 48 0.9× 143 3.2× 5 0.1× 33 0.8× 25 353

Countries citing papers authored by Lydie Hazan

Since Specialization
Citations

This map shows the geographic impact of Lydie Hazan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydie Hazan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydie Hazan more than expected).

Fields of papers citing papers by Lydie Hazan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydie Hazan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydie Hazan. The network helps show where Lydie Hazan may publish in the future.

Co-authorship network of co-authors of Lydie Hazan

This figure shows the co-authorship network connecting the top 25 collaborators of Lydie Hazan. A scholar is included among the top collaborators of Lydie Hazan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydie Hazan. Lydie Hazan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Morris, Sheldon, Claire Bristow, Michael R. Wierzbicki, et al.. (2020). Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. The Lancet Infectious Diseases. 21(5). 668–676. 65 indexed citations
2.
Balwani, Manisha, Herbert L. Bonkovsky, Karl E. Anderson, et al.. (2020). Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist. Blood. 136(Supplement 1). 51–51. 8 indexed citations
3.
Hazan, Lydie, et al.. (2019). Efficacy and Safety of Honey Bee Venom ( Apis mellifera) Dermal Injections to Treat Osteoarthritis Knee Pain and Physical Disability: A Randomized Controlled Trial. The Journal of Alternative and Complementary Medicine. 25(8). 845–855. 18 indexed citations
4.
Bowles, Vernon M, et al.. (2018). Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation. Pediatric Dermatology. 35(5). 616–621. 14 indexed citations
5.
Lawitz, E.J., Jacqueline Hill, Lydie Hazan, et al.. (2012). 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS. Journal of Hepatology. 56. S470–S471. 7 indexed citations
6.
Poordad, Fred, Jacob Lalezari, Eric Lawitz, et al.. (2012). 1151 CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL. Journal of Hepatology. 56. S455–S455. 4 indexed citations
7.
Läwitz, E., Lydie Hazan, Daniel Gruener, et al.. (2012). 1189 GS-9669, A NOVEL NS5B NON-NUCLEOTIDE SITE II INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY, FAVORABLE SAFETY PROFILE AND POTENTIAL FOR ONCE-DAILY DOSING. Journal of Hepatology. 56. S471–S471. 5 indexed citations
8.
Hazan, Lydie, et al.. (2012). Pharmacokinetics and Safety of 0.5% Ivermectin Lotion for Head Louse Infestations. Pediatric Dermatology. 30(3). 323–328. 8 indexed citations
9.
Manns, M.P., Melissa Palmer, Robert Flisiak, et al.. (2011). 126 A PHASE-2B TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A CASPASE INHIBITOR GS-9450, IN ADULTS FAILING PEG/RBV THERAPY FOR CHRONIC HCV INFECTION. Journal of Hepatology. 54. S55–S56. 3 indexed citations
10.
11.
Berezny, Katherine, Rakhi Kilaru, Daniel K. Benjamin, et al.. (2006). Racial differences are seen in blood pressure response to fosinopril in hypertensive children. American Heart Journal. 152(2). 394–399. 24 indexed citations
12.
Li, Jennifer S., Katherine Berezny, Rakhi Kilaru, et al.. (2004). Is the Extrapolated Adult Dose of Fosinopril Safe and Effective in Treating Hypertensive Children?. Hypertension. 44(3). 289–293. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abiodun Adefurin Breakdown of academic impact, for papers by Patrizia Morelli Breakdown of academic impact, for papers by Mahroo Rezaeinejad Breakdown of academic impact, for papers by Nicholas W. Carris Breakdown of academic impact, for papers by Nancy Greenberg Breakdown of academic impact, for papers by Parker Ra Breakdown of academic impact, for papers by Valentino Conti Breakdown of academic impact, for papers by Michaël Thy Breakdown of academic impact, for papers by Junko Mochizuki Breakdown of academic impact, for papers by Philip Macarthy
Rankless by CCL
2026